Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06880718 · ClinicalTrials.gov registry record · Phase 4
Injectable Buprenorphine in Prison: A Preference Trial
A Phase 4 study, sponsored by Lifespan.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT06880718 is a Phase 4 study that is actively recruiting participants, run by Lifespan. The registered enrollment target is 60 participants.
The verdict
NCT06880718, a Phase 4 study, is actively recruiting participants, sponsored by Lifespan.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
The goal of this pilot trial is to compare two branded extended-release buprenorphine (XR-B) formulations (Sublocade vs. Brixadi) to explore how they improve treatment retention after release from prison among incarcerated individuals with opioid use disorder (OUD) who are transitioning back into the community. The main question it aims to answer are: How do Sublocade and Brixadi compare in terms of feasibility, acceptability, and effectiveness? Does giving people a choice of medication affect how well they stay in treatment? Using a partially randomized preference trial approach, there will be a comparison between participants who choose their XR-B formulation to those who are randomly assigned to see if patient preference influences treatment outcomes. The trial is a hybrid implementation-effectiveness trial. Participants will: * Choose which medication they prefer or be randomly assigned if they don't have a preference. * Receive monthly injections of either Sublocade or Brixadi before and after release from prison. * Complete surveys and clinical assessments on treatment experience and acceptability. * Be monitored for treatment retention, opioid use, and adverse events for six months post-release. Researchers will compare the two treatments to see which one works better for people leaving prison and if allowing people to choose their treatment improves results.
Interventions
- DRUG Brixadi (Injectable Buprenorphine)
- DRUG Sublocade
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-02-18 |
| Est. Completion | 2027-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06880718
The ClinicalTrials.gov registry entry for NCT06880718 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lifespan, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Brixadi (Injectable Buprenorphine) is the first listed.
NCT06880718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06880718 about?
NCT06880718 is a clinical study titled "Injectable Buprenorphine in Prison: A Preference Trial". The goal of this pilot trial is to compare two branded extended-release buprenorphine (XR-B) formulations (Sublocade vs. Brixadi) to explore how they improve treatment retention after release from prison among incarcerated individuals with opioid use disorder (OUD) who are transitioning back into th...
What is the current status of trial NCT06880718?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2026-02-18. Estimated completion is 2027-06.
What interventions are being tested in trial NCT06880718?
The interventions under investigation include: Brixadi (Injectable Buprenorphine) (DRUG), Sublocade (DRUG).
Who is sponsoring clinical trial NCT06880718?
This trial is sponsored by Lifespan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.